Kapoun, Ann M.

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences

Wnt/β-catenin signaling in development and cancerHedgehog Signaling Pathway Studies

Cited by 614

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 138

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., Hool, H., Leach, J. W., Sanchez, J., Sohal, D. P. S., et al. (2019) · Cancer Medicine

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 82

Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 74

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

Zhang, M., Haughey, M., Wang, N.-Y., Blease, K., Kapoun, A. M., Couto, S., Belka, I., Hoey, T., Groza, M., Hartke, J., et al. (2020) · PLOS ONE

Wnt/β-catenin signaling in development and cancerLiver physiology and pathology

Cited by 48

Safety and Preliminary Efficacy Results of a Phase I First‐in‐Human Study of the Novel Notch‐1 Targeting Antibody Brontictuzumab (OMP‐52M51) Administered Intravenously to Patients with Hematologic Malignancies

Casulo, C., Ruan, J., Dang, N. H., Gore, L., Diefenbach, C., Beaven, A. W., Castro, J. E., Porcu, P., Faoro, L., Dupont, J., et al. (2016) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 35